



Press Release



**A dynamic progression in revenue: + 128% to reach 1.7 M€
for the 1st half of 2014/15**

January 8, 2015, Montpellier, France. MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, is pleased to announce its figures for the 2nd quarter ended December 31, 2014.

<i>In thousands of Euros</i>	2013/2014	2014/2015
Q1 Revenue	82	625
Q2 Revenue	658	1 063
1st half Revenue	740	1 688

Growth confirmed for Q2

During the 2nd quarter of its 2014/2015 financial year, a strong growth in Medtech's revenue was maintained with the sale of three new ROSA™ devices including two in the United States (University of Alabama, Birmingham, Alabama and the University of California, Irvine, California).

At the end of the 1st half of the 2014/2015 financial year, Medtech's revenue stood at 1.7 M€, up 128% compared with the first six months of 2013/2014.

Thanks to the dynamic evolution of its fleet of devices under maintenance contract, sales of services have reached 151 K€ for the first half of the current financial year compared with 107 K€ for the previous year.

As of December 31, 2014, the number of ROSA™ robots delivered throughout the world has reached 33 (this includes 5 delivered during the second half of 2014/2015). Medtech has performed outstandingly in pursuing commercial deployment in line with its development plan.

Management strengthening

Michael Christ has recently joined Medtech as « *Director of Regulatory Affairs* » to accompany the firm in its development program and marketing of new products including ROSA™ Spine. Michael Christ has a background of over 10 years in the fields of quality systems management and regulatory affairs for medical devices and pharmaceutical instruments.

Besides this, Francis Lesueur has also joined Medtech as « *Director of Manufacturing & Supply Chain* », bringing the company his expert knowledge of improving manufacturing processes to



Press Release

accompany the expected high sales growth. Francis Lesueur has over 15 years in the aeronautics, automobile and medical industries and, after 2008, held similar positions at Supersonic Imagine.

Bertin Nahum, CEO and Founder of Medtech said: « *The solid second half of 2014 that we have just completed clearly reflects our strategy to conquer international markets and the pledge we made at the time of our IPO. These recent developments will help to reinforce Medtech's position as a European leader in surgical robotics* ».

He added: « I am pleased to welcome Michael Chris and Francis Lesueur who, in their respective functions, will take an active part in creating company value».

Medtech shares may be incorporated into equity savings plans for small to medium-sized companies which benefit from the same tax advantages as a traditional equity savings plan.

About MEDTECH

Founded in 2002 by Bertin NAHUM and based near Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.

In 2007, MEDTECH developed ROSA™, a state-of-the-art technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.

In 2013 Medtech received the « European Company of the Year Award » in the “robotic neurosurgery” category from Frost & Sullivan.

In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine.

In October 2014, MEDTECH won the « Révélation » prize in the Mediterranean Deloitte Technology Fast 50 Awards.

CONTACT MEDTECH

Christophe Sibillin
Chief Financial Officer
Tel : +33 (0)4 67 10 77 40

INVESTORS

Corinne Puissant
Tel : +33 (0)1 53 67 36 57
cpuissant@actus.fr

PRESS

Alexandra Prisa
Tel. : +33(0)1 53 67 35 79
aprisa@actus.fr